News & Updates

In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

The University of Hong Kong (HKU) has launched a precision oncology programme in partnership with public and private stakeholders to provide free comprehensive genomic profiling tests to 1,800 eligible patients with stage IV non-small-cell lung cancer (NSCLC) in Hong Kong. Initial data from the programme revealed less common mutations amenable to treatment with targeted therapies in a sizeable proportion of patients.

Among pregnant individuals on antiretroviral therapy (ART) for HIV-1 infection, those on dolutegravir had the greatest viral suppression rates at delivery, a recent US-based observational study showed. However, birth outcomes generally did not differ between dolutegravir recipients and those on various other ART regimens.

A polygenic liability for major depressive disorder and bipolar disorder contributes to improvements following electroconvulsive therapy (ECT), reports a study. This provides evidence of a genetic factor for clinical response to ECT.